Learn about our sponsored testing program and how it can benefit both patients and healthcare providers.
Find out how our Candida auris polymerase chain reaction assay detects and identifies C. auris from surveillance swabs.
Helicobacter pylori, or H. pylori, is one of the world’s most common chronic bacterial infections. Estimated to impact 4.4 billion individuals globally, H. pylori affects 35% to 89% of children, depending the on the geographic region in...
Bone and Soft Tissue Pathology Services at Mayo Cinic Laboratories
At Mayo Clinic, we excel in our approach to work collaboratively with radiology, surgery, and clinical practice to bring the highest quality.
Cytopathology Services at Mayo Clinic Laboratories
Pathologists from across the world send cases for the cytopathology section at Mayo Clinic to review. Learn more.
Test panel guides diagnosis of early onset IBD: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy...
Testing Archives - Page 25 of 26 - Insights
Skip to Content MayoACCESS MayoLINK...
New tests launched in April - Insights
In April 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...
Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.